Abstract
AMPK: AMP-activated protein kinase; CHX: cycloheximide; RAD001: everolimus; HBSS: Hanks' balanced salt solution; LC-MS/MS: liquid chromatography-mass spectrometry/mass spectrometry; MMP14: matrix metallopeptidase 14; MTOR: mechanistic target of rapamycin kinase; MAPK: mitogen-activated protein kinase; RB1CC1/FIP200: RB1 inducible coiled-coil 1; PtdIns3P: phosphatidylinositol-3-phosphate; PX: phox homology; SH3: Src homology 3; SH3PXD2A/TKS5: SH3 and PX domains 2A; SH3PXD2A-[6A]: S112A S142A S146A S147A S175A S348A mutant; ULK1: unc-51 like autophagy activating kinase 1.
Keywords:
MMP14; SH3PXD2A; ULK1; cellular migration; ovarian cancer.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
AMP-Activated Protein Kinases / metabolism
-
Adaptor Proteins, Vesicular Transport
-
Autophagy*
-
Autophagy-Related Protein-1 Homolog / metabolism
-
Cell Movement
-
Chromatography, Liquid
-
Female
-
Humans
-
Intracellular Signaling Peptides and Proteins
-
Matrix Metalloproteinase 14
-
Ovarian Neoplasms*
-
TOR Serine-Threonine Kinases / metabolism
-
Tandem Mass Spectrometry
Substances
-
Matrix Metalloproteinase 14
-
AMP-Activated Protein Kinases
-
TOR Serine-Threonine Kinases
-
Adaptor Proteins, Vesicular Transport
-
Autophagy-Related Protein-1 Homolog
-
MMP14 protein, human
-
MTOR protein, human
-
SH3PXD2A protein, human
-
ULK1 protein, human
-
Intracellular Signaling Peptides and Proteins
Grants and funding
This study was financially supported by grants from the National Science and Technology Council, Taiwan (111-2314-B-182A-035-MY3 to CLT; 110-2314-B-182-033 to CNT; 111-2314-B-182A-088 to CYL) and Chang Gung Medical Research Foundation, Taiwan (CMRPG3L1431, CMRPG3M0801, and CMRPG3M1291 to CLT, CMRPG3M0761 to CYL).